Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.24.3
Segment Information (Tables)
9 Months Ended
Sep. 28, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information
The following tables present our segment information for the 13 and 39 weeks ended September 28, 2024 and September 30, 2023 (in $000’s):
Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023
Revenues
Biotechnology $ —  $ —  $ —  $ — 
Fintech 4,941  —  7,110  — 
Discontinued operations —  —  —  3,795 
Total Revenues $ 4,941  $ —  $ 7,110  $ 3,795 
Gross profit
Biotechnology $ —  $ —  $ —  $ — 
Fintech 2,361  —  3,459  — 
Discontinued operations —  —  —  (197)
Total Gross profit $ 2,361  $ —  $ 3,459  $ (197)
Operating income (loss)
Biotechnology $ (1,574) $ (764) $ (6,557) $ (2,923)
Fintech 353  —  614  — 
Discontinued operations —  —  —  14,158 
Total Operating income (loss) $ (1,221) $ (764) $ (5,943) $ 11,235 
Depreciation and amortization
Biotechnology $ 438  $ 363  $ 1,604  $ 1,090 
Fintech 536  —  715  — 
Discontinued operations —  —  —  96 
Total Depreciation and amortization $ 974  $ 363  $ 2,319  $ 1,186 
Interest (income) expense, net
Biotechnology $ (363) $ (758) $ (272) $ (1,598)
Fintech 110  —  267  — 
Discontinued operations —  —  —  181 
Total Interest expense, net $ (253) $ (758) $ (5) $ (1,417)
Net income (loss) before income taxes
Biotechnology $ (1,897) $ (267) $ (7,228) $ (1,094)
Fintech 558  —  1,408  — 
Discontinued operations —  —  —  13,976 
Total Net income before income taxes $ (1,339) $ (267) $ (5,820) $ 12,882